Cannara Financial Statements From 2010 to 2025
| LOVFF Stock | USD 0.62 0.04 6.90% |
Check Cannara Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cannara Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Cannara financial statements analysis is a perfect complement when working with Cannara Biotech Valuation or Volatility modules.
Cannara |
Cannara Biotech OTC Stock Return On Asset Analysis
Cannara Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Cannara Biotech Return On Asset | 0.0327 |
Most of Cannara Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cannara Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Cannara Biotech has a Return On Asset of 0.0327. This is 100.37% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is 123.36% lower than that of the firm.
Cannara Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Cannara Biotech's current stock value. Our valuation model uses many indicators to compare Cannara Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cannara Biotech competition to find correlations between indicators driving Cannara Biotech's intrinsic value. More Info.Cannara Biotech is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.75 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Cannara Biotech is roughly 1.33 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cannara Biotech's earnings, one of the primary drivers of an investment's value.About Cannara Biotech Financial Statements
Cannara Biotech stakeholders use historical fundamental indicators, such as Cannara Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cannara Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cannara Biotech's assets and liabilities are reflected in the revenues and expenses on Cannara Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cannara Biotech. Please read more on our technical analysis and fundamental analysis pages.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. Cannara Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Cannara OTC Stock
Cannara Biotech financial ratios help investors to determine whether Cannara OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cannara with respect to the benefits of owning Cannara Biotech security.